Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension

Anesthesiology

Volumn 92, Issue 6, 2000, Pages 1702-1712

  Weimann, Jörg ^a   Ullrich, Roman ^d   Hromi, Jonathan ^d   Fujino, Yuji ^d   Clark, Martin W H ^b   Bloch, Kenneth D ^d   Zapol, Warren M ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NONE

Author keywords

PDE5; Phosphodiesterase

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; SILDENAFIL; THROMBOXANE DERIVATIVE; ZAPRINAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; STOMACH INTUBATION; VASODILATATION; WAKEFULNESS;

EID: 0034047308     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200006000-00030     Document Type: Article

References (47)

1. Knowles RG, Moncada S: Nitric oxide synthases in mammals. Biochem J 1994; 298:249-58
2. Moncada S, Palmer RM, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:109-42
3. Schmidt HH, Lohmann SM, Walter U: The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action. Biochim Biophys Acta 1993; 1178:153-75
4. Lincoln TM, Cornwell TL: Intracellular cyclic GMP receptor proteins. FASEB J 1993; 7:328-38
5. Beavo JA: Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995; 75:725-48
6. Soderling SH, Bayuga SJ, Beavo JA: Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998; 273:15553-8
7. Fisher D, Smith J, Pillar J, Denis SS, Cheng J: Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem 1998; 273:15559-64
8. Ahn HS, Foster M, Cable M, Pitts BJR, Sybertz EJ: Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991; 308:191-7
9. Braner DA, Fineman JR, Chang R, Soifer SJ: M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 1993; 264:H252-8
10. McMahon TJ, Ignarro LJ, Kadowitz PJ: Influence of zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol 1993; 74:1704-11
11. Eddahibi S, Raffestin B, Le Monnier de Gouville AC, Adnot S: Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br J Pharmacol 1998; 125:681-8
12. Cohen AH, Hanson K, Morris K, Fouty B, McMurtry IF, Clarke W, Rodman DM: Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996; 97:172-9
13. Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH: Dipyridamole potentiates pulmonary vasodilation induced by acetyl-choline and nitric oxide in the ovine fetus. Am J Respir Crit Care Med 1998; 157:1104-10
14. Clarke WR, Uezono S, Chambers A, Doering EB: The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance. Pulm Pharmacol 1994; 7:81-9
15. Delpy E, Le Monnier de Gouville AC: Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: In vitro and in vivo characterization. Br J Pharmacol 1996: 118:1377-84
16. Thusu KG, Morin FC3, Russell JA, Steinhorn RH: The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric-oxide. Am J Respir Crit Care Med 1995; 152:1605-10
17. Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH: Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol 1995; 269:H473-9
18. Ichinose F, Adrie C, Hurford WE, Zapol WM: Prolonged pulmonary vasodilator action of inhaled nitric oxide by zaprinast in awake lambs. J Appl Physiol 1995; 78:1288-95
19. Fullerton DA, Jaggers J, Piedalue F, Grover FL, McIntyre RC Jr: Effective control of refractory pulmonary hypertension after cardiac operations. J Thorac Cardiovasc Surg 1997; 113:363-70
20. Ziegler JW, Ivy DD, Wiggins JW, Kinsella JP, Clarke WR, Abman SH: Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med 1998; 158:1388-95
21. Fitzgerald GA: Dipyridamole. N Engl J Med 1987; 316:1247-57
22. Gresele P, Arnout J, Deckmyn H, Vermylen J: Mechanisms of the antiplatelet action of dipyridamole in whole blood: Modulation of adenosine concentration and activity. Thromb Haemost 1986; 55:12-8
23. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ: Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78:257-61
24. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C: Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase Inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8:47-52
25. Cheitlin MD, Hutter AM, Brindis RG, Ganz P, Kaul S, Russell RO, Zusman RM: Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999; 99:168-77
26. McLean RF, Prielipp RC, Rosenthal MH, Pearl RG: Vasodilator therapy in microembolic porcine pulmonary hypertension. Anesth Analg 1990; 71:35-41
27. Prielipp RC, McLean R, Rosenthal MH, Pearl RG: Hemodynamic profiles of prostaglandin El, isoproterenol, prostacyclin, and nifedipine in experimental porcine pulmonary hypertension. Crit Care Med 1991; 19:60-7
28. Cooper JD, Muirhead DC, Taylor JE, Baker PR: Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace enrichment of dialysates and high-performance liquid chromatography. J Chromatogr B 1997; 701:87-95
29. Rovira I, Chen TY, Winkler M, Kawai N, Bloch KD, Zapol WM: Effects of inhaled nitric oxide on pulmonary hemodynamics and gas exchange in an ovine model of ARDS. J Appl Physiol 1994; 76:345-55
30. Dent G, Magnussen H, Rabe KF: Cyclic nucleotide phosphodiesterases in the human lung. Lung 1994; 172:129-46
31. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA: Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338:1397-404
32. Barry EA, DeFelice AF, Papoian T: Viagra Tablets. NDA #20-895. Review and evaluation of pharmacology and toxicology data. Center for Drug Evaluation and Research of the US Food and Drug Administration 1998; http://www.fda.gov/cder/news/viagra.htm
33. Jackson G, Benjamin N, Jackson N, Allen MJ: Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999; 83:13C-20C
34. Ballard SA, Gingell JC, Tang K, Turner LA, Price ME, Naylor AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159:2164-71
35. Naylor AM: Endogenous neurotransmitters mediating penile errection. Br J Urol 1998; 81:424-31
36. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326:90-4
37. Hamet P, Pang SC, Tremblay J: Atrial natriuretic factor-induced egression of cyclic guanosine 3′:5′-monophosphate in cultured vascular smooth muscle and endothelial cells. J Biol Chem 1989; 264: 12364-9
38. Archer SL, Tolins JP, Raij L, Weir EK: Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium derived relaxing factor. Biochem Biophys Res Commun 1989; 164:1198-205
39. Brashers VL, Peach MJ, Rose CE Jr: Augmentation of hypoxic pulmonary vasoconstriction in the isolated perfused rat lung by in vitro antagonists of endothelium-dependent relaxation. J Clin Invest 1988; 82:1495-502
40. Liu S, Crawley DE, Barnes PJ, Evans TW: Endothelium-derived relaxing factor inhibits hypoxlc pulmonary vasoconstriction in rats.Am Rev Respir Dis 1991; 143:32-7
41. Ichinose F, Adrie C, Hurford WE, Bloch KD, Zapol WM: Selective pulmonary vasodilation induced by aerosolized zaprinast. ANESTHESIOLOGY 1998; 88:410-6
42. Adrie C, Hirani WM, Holzmann A, Keefer L, Zapol WM, Hurford WE: Selective pulmonary vasodilation by intravenous infusion of an ultrashort half-life nucleophile/nitric oxide adduct. ANESTHESIOLOGY 1998; 88:190-5
43. Petros A, Bennett D, Vallance P: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338:1557-8
44. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, Davis KJ, Hyers TM, Papadakos P: Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase II trial. Crit Care Med 1998; 26:15-23
45. Roberts JD Jr, Fineman JR, Morin FC 3, Shaul PW, Rimar S, Schreiber MD, Polin RA, Zwass MS, Zayek MM, Gross I, Heymann MA, Zapol WM: Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997; 336:605-10
46. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM: Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399-405
47. Loughney K, Martins J, Harris EA, Sadhu K, Hicks JB, Sonnenburg WK, Beavo JA: Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3′,5′-cyclic nucleotide phosphodiesterases. J Biol Chem 1996; 271:796-806